Armistice Capital, LLC Increases Stake in Agios Pharmaceuticals to 4.57%

On May 15, 2026, Armistice Capital, LLC and its managing member Steven Boyd filed a Schedule 13G/A regarding their holdings in Agios Pharmaceuticals, Inc. (AGIO). The filing reveals that the reporting persons beneficially own 2,716,000 shares of common stock, representing a 4.57% ownership stake in the company. This represents an increase from a previous 0% position as of the last reporting period. Armistice Capital serves as the investment manager for the Armistice Capital Master Fund Ltd., which is the direct holder of the shares. Under the terms of their Investment Management Agreement, Armistice Capital exercises shared voting and dispositive power over the securities. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. Consequently, the reporting persons now hold a significant minority position in the Cambridge-based pharmaceutical company.